[{"data":1,"prerenderedAt":179},["ShallowReactive",2],{"drug-naltrexone":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":79,"warnings":88,"renal":89,"monitoring":90,"interactions":91,"review":92,"examples":95,"atc":106,"iran":108,"usApproval":128,"links":134,"populations":153},"naltrexone",1,{"fa":7,"en":8},"نالترکسون","Naltrexone","nervous-system",{"fa":11,"en":12},"آنتاگونیست اپیوئید","Opioid antagonist",[14],{"name":15,"market":16},"Revia","US",[18,19,7],"revia","رویا",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-50","tablet","oral","50 mg tablet (scored)",{"amount":27,"unit":28,"perUnit":23,"scored":29},50,"mg",true,[16],[32],{"source":33,"section":34},"fda-naltrexone","How Supplied",[36,58],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":48,"notes":51},"alcohol","alcohol-use-disorder",{"fa":40,"en":41},"وابستگی به الکل — ۵۰ mg یک بار در روز","Alcohol dependence — 50 mg once daily",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":27,"dosesPerDay":5},[49],{"source":33,"section":50},"Dosage and Administration — Alcoholism",[52],{"text":53,"refs":56},{"fa":54,"en":55},"در کارآزمایی‌ها تا ۱۲ هفته؛ فقط بخشی از برنامه درمان جامع.","Studied for up to 12 weeks; only part of a comprehensive programme.",[57],{"source":33,"section":50},{"id":59,"disease":60,"label":61,"population":64,"type":46,"unit":28,"dose":66,"refs":67,"notes":70},"opioid","opioid-use-disorder",{"fa":62,"en":63},"پیشگیری از عود اپیوئید (پس از سم‌زدایی) — شروع ۲۵ mg، سپس ۵۰ mg روزانه","Opioid relapse prevention (after detox) — start 25 mg, then 50 mg daily",{"minAge":65},{"value":44,"unit":45},{"perDose":27,"dosesPerDay":5},[68],{"source":33,"section":69},"Dosage and Administration — Treatment of Opioid Dependence",[71],{"text":72,"refs":75},{"fa":73,"en":74},"دوز اول ۲۵ mg؛ اگر علائم ترک نبود، ۵۰ mg روزانه. بیمار باید ۷ تا ۱۰ روز بدون اپیوئید باشد (تست ادرار منفی یا تست نالوکسان).","First dose 25 mg; if no withdrawal, 50 mg daily. Patient must be opioid-free for 7–10 days (negative urine screen or naloxone challenge).",[76,77],{"source":33,"section":69},{"source":33,"section":78},"Contraindications",[80],{"id":81,"severity":82,"text":83,"refs":86},"ci","block",{"fa":84,"en":85},"مصرف مسکن اپیوئیدی؛ وابستگی فعلی به اپیوئید (از جمله متادون یا بوپرنورفین)؛ ترک حاد اپیوئید؛ تست نالوکسان ناموفق یا ادرار مثبت؛ حساسیت.","Receiving opioid analgesics; current opioid dependence (including methadone or buprenorphine); acute opioid withdrawal; failed naloxone challenge or positive urine screen; hypersensitivity.",[87],{"source":33,"section":78},[],[],[],[],{"status":93,"reviewer":94,"date":94},"unverified",null,[96,101],{"regimen":37,"formulation":22,"input":97,"expect":100},{"ageYears":98,"weightKg":99},40,80,{"perDose":27,"tabletsPerDoseRounded":5},{"regimen":59,"formulation":22,"input":102,"expect":105},{"ageYears":103,"weightKg":104},30,70,{"perDose":27,"tabletsPerDoseRounded":5},[107],"N07BB04",{"status":109,"forms":110,"refs":123},"registered",[111,115,119],{"code":112,"en":113,"fa":114},"01718","NALTREXONE HCL 25MG CAP","کپسول نالترکسون هیدروکلراید ۲۵ میلی‌گرم",{"code":116,"en":117,"fa":118},"01719","NALTREXONE HCL 50MG CAP","کپسول نالترکسون هیدروکلراید ۵۰ میلی‌گرم",{"code":120,"en":121,"fa":122},"51777","NALTREXONE INJECTION, POWDER, FOR SUSPENSION PARENTERAL 380 mg","پودر برای تهیه سوسپانسیون تزریقی نالترکسون ۳۸۰ میلی‌گرم",[124],{"source":125,"section":126,"url":127},"darooyab-generic","G-1970\u002FNaltrexone","https:\u002F\u002Fwww.darooyab.ir\u002FG-1970\u002FNaltrexone",{"kind":129,"refs":130,"id":133},"ANDA",[131],{"source":33,"section":132},"SPL approval \u002F marketing category","ANDA076264",[135,138,142,145,148,151],{"kind":136,"url":137,"label":133},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=076264",{"kind":139,"url":140,"label":141},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=06ff2d5a-e62b-4fa4-bbdb-01938535bc65","FDA Naltrexone",{"kind":143,"url":144,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa685041.html",{"kind":143,"url":146,"label":147},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa609007.html","Naltrexone Injection",{"kind":149,"url":150,"label":107},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N07BB04",{"kind":152,"url":127,"label":8},"darooyab",{"pregnancy":154,"lactation":163,"pediatric":171},{"level":155,"text":156,"quote":159,"refs":160},"caution",{"fa":157,"en":158},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Teratogenic Effects Category C Naltrexone has been shown to increase the incidence of early fetal loss when given to rats at doses ≥ 30 mg\u002Fkg\u002Fday (180 mg\u002Fm 2 \u002Fday; 5 times the recommended therapeutic dose, based on body surface area) and to rabbits at oral doses ≥ 60 mg\u002Fkg\u002Fday (720 mg\u002Fm 2 \u002Fday; 18 times the …",[161],{"source":33,"section":162},"Pregnancy",{"level":155,"text":164,"quote":167,"refs":168},{"fa":165,"en":166},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Because many drugs are excreted in human milk, caution should be exercised when naltrexone hydrochloride is administered to a nursing woman.",[169],{"source":33,"section":170},"Nursing Mothers",{"level":155,"text":172,"quote":175,"refs":176},{"fa":173,"en":174},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safe use of naltrexone hydrochloride in pediatric patients younger than 18 years old has not been established.",[177],{"source":33,"section":178},"Pediatric Use",1792115189763]